Literature DB >> 12706927

Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology.

Flavio Tarasoutchi1, Max Grinberg, Guilherme S Spina, Roney O Sampaio, L uís F Cardoso, Eduardo G Rossi, Pablo Pomerantzeff, Francisco Laurindo, Protásio L da Luz, José Antônio F Ramires.   

Abstract

OBJECTIVES: This study was designed to assess the feasibility and the long-term results of a symptom-based strategy of aortic valve replacement in a Brazilian population with predominant rheumatic etiology.
BACKGROUND: Optimal criteria for valve replacement in aortic regurgitation (AR) are still not entirely clear. The appearance of symptoms is an indication for surgery, but may be associated with myocardial damage. Although cardiac imaging data have provided a safer guide for such decisions, the use of symptom-based surgical indication has not been validated and might conceivably be better in populations with predominant rheumatic etiology and younger age.
METHODS: Echocardiography and rest-exercise radionuclide ventriculography were performed in 75 patients with severe AR, age 28 +/- 9 years, over a period of 10 +/- 0.69 years. Thirty-seven patients developed symptoms and underwent aortic valve replacement surgery within six months. Thirty-eight patients remained asymptomatic and were managed medically.
RESULTS: Survival was 100% in asymptomatic patients and 82% in symptomatic. Surgical treatment caused marked ventricular remodeling, with ventricular diameter involution and an improvement of rest-exercise ejection fraction percent variation. Multivariate analysis showed that the probability of developing symptoms within 10 years was 58% for a patient with a left ventricular end-diastolic diameter > or =70 mm and 76% for a patient with left ventricular end-systolic (LVESD) > or =50 mm. Logistic regression identified LVESD and age as the most predictive and specific, but not sensitive, indicators of symptom development.
CONCLUSIONS: Application of a standardized therapeutic strategy to patients with severe AR and predominant rheumatic etiology resulted in 90.6% survival after 10 years of follow-up.

Entities:  

Mesh:

Year:  2003        PMID: 12706927     DOI: 10.1016/s0735-1097(03)00129-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

Review 1.  Outcomes following transcatheter aortic valve replacement in patients with native aortic valve regurgitation.

Authors:  Tamunoinemi Bob-Manuel; Siri Kadire; Mark R Heckle; Jiajing Wang; Uzoma N Ibebuogu
Journal:  Ann Transl Med       Date:  2018-01

2.  Predicting left ventricular recovery after replacement of a regurgitant aortic valve in pediatric and young adult patients: is it ever too late?

Authors:  Daniel A Cox; Kara Walton; Peter J Bartz; James S Tweddell; Peter C Frommelt; Michael G Earing
Journal:  Pediatr Cardiol       Date:  2012-10-09       Impact factor: 1.655

Review 3.  Are vasodilators still indicated in the treatment of severe aortic regurgitation?

Authors:  Jocelyn Inamo; Maurice Enriquez-Sarano
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

4.  EuroSCORE models in a cohort of patients with valvular heart disease and a high prevalence of rheumatic fever submitted to surgical procedures.

Authors:  Ricardo Casalino; Flávio Tarasoutchi; Guilherme Spina; Marcelo Katz; Antonio Bacelar; Roney Sampaio; Otavio T Ranzani; Pablo M Pomerantzeff; Max Grinberg
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.